The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Curonix Expands the Freedom® PNS System Patient Treatment Options with the Launch of its Innovative Wearable Solution for Chronic Pain of the Head, Neck, Shoulder, and Torso

POMPANO BEACH, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company specializing in opioid-free chronic pain relief, today announced the launch of its next-generation wearable accessory for the Freedom® Peripheral Nerve Stimulator (PNS) System. This innovative wearable targets chronic pain in the head, neck, shoulder, and upper torso regions, with the potential to serve up to 235,000 patients annually1.

This addition completes an already robust portfolio that provides physicians and patients with an effective solution for managing chronic pain and ensuring every targeted treatment area has a dedicated wearable, fulfilling Curonix’s mission to deliver the only full-body PNS system on the market.

Curonix’s wearable portfolio is designed for three core advantages: flexibility, versatility, and comfort through a slip-resistant, adjustable fit that accommodates a wide range of body types for consistent therapy delivery. With multiple configurations, a single wearable can precisely target nerve locations. The lightweight, low-profile designs support adhesive-free wear over clothing while maintaining therapy connectivity and power, ensuring comfort and confidence in daily activities.

“With more than 20,000 patients treated, the Freedom PNS System is helping patients regain control over their daily lives,” said Aure Bruneau, Chief Executive Officer of Curonix. “The addition of this innovative wearable completes the only full-body PNS portfolio, giving patients and physicians dedicated solutions for every major targeted peripheral nerve. By expanding our clinical reach while prioritizing patient comfort, we are broadening the potential of what PNS can achieve.”

The Freedom® PNS System has been cleared for use in the craniofacial region but is not yet commercially available.

For more information, visit curonix.com.

References:

  1. Data on file with Curonix


About Curonix LLC

Curonix LLC is a Delaware medical technology company dedicated to developing and commercializing innovative therapies intended to help relieve chronic pain. The proprietary Freedom PNS System is a non-integrated, minimally-invasive implant that does not include an implanted battery. The Freedom PNS System is powered by HF-EMC (High-Frequency Electromagnetic Coupling) and is comprised of a two-component implantable neurostimulator, an externally worn transmitter, and software used to set patient-specific stimulation programs. The two-component neurostimulator, comprised of an electrode array and a separate surgically connected receiver, is anchored within two separate incisions, including the creation of a subcutaneous pocket. The stimulation program is adjusted as needed to provide pain relief for the patient. For more information, visit curonix.com.

Contact Information:

Ashley Brown
Sr. Director of Marketing & Communications, Curonix
Ashley.Brown@curonix.com
512-791-4743

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/d857ab83-00fc-48b0-a997-85fac8a31671


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.